Compass Therapeutics, Inc.
NASDAQ:CMPXBiotechnology
-$0.03 today
- Market cap
- $109.26M
- Beta
- 0.74
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.37
Volume 2.90M
Average 7.64M
CMPX Total Liabilities
Everything the company owes to creditors and other parties.
Compass Therapeutics, Inc.NASDAQ: CMPX
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities falls 11.7% from a year ago
Total liabilities stood at $18.7M at the end of Q1 FY2026, down 11.7% from a year earlier and down 18.0% from the prior quarter. Over 3 fiscal years it compounded at +8.2% a year.
Context
- Total liabilities amounted to 9.1% of total assets at the end of Q1 FY2026, down 7.0 pp from a year earlier.
- Total liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps falling in the next quarterly balance sheet after a -11.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 22.8M USD
- Year-over-year change
- +50.3%
- 4-year CAGR
- +13.6%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 22.8M | +50.3% |
| FY2024 | 2024-12-31 | 15.17M | +82.0% |
| FY2023 | 2023-12-31 | 8.34M | -53.7% |
| FY2022 | 2022-12-31 | 18.01M | +31.6% |
| FY2021 | 2021-12-31 | 13.68M | — |
Total Liabilities vs competitors
How CMPX compares with its peers on the latest reported figures
- CMPX's Mar 2026 total liabilities of $18.7M is the 8th highest of the 11 companies compared; the peer median is $63.52M.
- Its year-over-year change of -11.7% is the 7th highest of 10, against a peer median of +1.2%.
- Total liabilities amounts to 9.1% of total assets for CMPX, versus a peer median of 19.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $349.51M | -22.1% | -4.0% | 122.1% | |
| Dec 2025 | $338.09M | — | — | 100.8% | |
| Mar 2026 | $290.38M | +1.2% | +4.3% | 225.3% | |
| Mar 2026 | $98.08M | -31.7% | -8.4% | 15.0% | |
| Mar 2026 | $65.96M | -62.2% | +0.1% | 24.5% | |
| Mar 2026 | $61.07M | +32.7% | +26.0% | 11.9% | |
| Mar 2026 | $51.1M | +5.3% | +17.1% | 89.8% | |
| Mar 2026 | $18.7M | -11.7% | +8.2% | 9.1% | |
| Mar 2026 | $13.47M | -4.9% | -14.6% | 3.9% | |
| Mar 2026 | $12.52M | +23.8% | -6.5% | 4.9% | |
| Mar 2026 | $2.59M | +73.6% | -2.7% | 1.9% | |
| Peer median (excluding CMPX) | $63.52M | +1.2% | -2.7% | 19.8% | |
Competitors are the stored peer set for CMPX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 144.51M | 34.95M | 24.23M | 43.48M | 30.64M |
| Short-term Investments | 0 | 151.66M | 128.23M | 83.24M | 178.26M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 8.18M | 1.42M | 6.03M | 913K |
| Total Current Assets | 147.11M | 194.79M | 153.88M | 132.75M | 209.82M |
| Property, Plant & Equipment (Net) | 6.33M | 4.53M | 2.67M | 7.08M | 9.2M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 320K | 320K | 320K | 568K | 568K |
| Total Non-current Assets | 6.65M | 4.85M | 2.99M | 7.65M | 9.77M |
| Total Assets | 153.76M | 199.65M | 156.88M | 140.4M | 219.59M |
| Account Payables | 867K | 3.38M | 4.09M | 2.25M | 1.59M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.6M | 1.56M | 1.94M | 2.79M | 2.68M |
| Total Current Liabilities | 10.63M | 16.17M | 7.8M | 8.87M | 13.97M |
| Long-term Debt | 0 | 0 | 0 | 0 | 8.83M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 1K | 0 |
| Total Non-current Liabilities | 3.05M | 1.84M | 536K | 6.3M | 8.83M |
| Total Liabilities | 13.68M | 18.01M | 8.34M | 15.17M | 22.8M |
| Common Stock | 10K | 13K | 13K | 13K | 18K |
| Retained Earnings | (233.59M) | (272.81M) | (315.31M) | (364.68M) | (431.17M) |
| Accumulated OCI | 0 | (302K) | 37K | 210K | 280K |
| Other Stockholders Equity | (0) | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 140.08M | 181.64M | 148.54M | 125.23M | 196.79M |
| Total Debt | 4.04M | 2.94M | 1.73M | 6.63M | 9.83M |
| Net Debt | (140.48M) | (32.01M) | (22.5M) | (36.85M) | (20.81M) |
Compass Therapeutics, Inc.
NASDAQ:CMPX
Intrinsic Alpha fair value
Locked
Current Price
$0.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.